As the industry increasingly shifts its attention to biologics, more attention is being paid to the prospect of developing biotherapeutics against membrane-bound targets. For these large target classes, biologics offer improved selectivity, an alternative for targets with known function that have not been amenable to small molecule drugs and the po
27-28 September 2023